Integrating Nanotechnology into Cancer Care
Integrating Nanotechnology into Cancer Care
复制标题
DOI：
10.1021/acsnano.9b04266
复制
发表时间：
2019-07-01
期刊：
影响因子：
17.1
通讯作者：
Gabizon, Alberto
中科院分区：
文献类型：
--
作者：
Grodzinski, Piotr;Kircher, Moritz;Gabizon, Alberto
在过去的15年里，医疗和癌症纳米技术的研究活动急剧增长。该领域已成为多学科研究的摇篮，汇集了物理学家，化学家和工程师，与临床医生和生物学家一起解决癌症护理和治疗中的首要问题。一些人认为，研究论文数量的爆炸并没有伴随着纳米医学的足够临床活动。然而，在过去的三年里，美国食品和药物管理局（FDA）已经批准了三种新的纳米药物，证实了纳米技术方法在癌症中的有效性。令人兴奋的是，翻译管道包含几个额外的有趣的候选者。在这篇Nano Focus文章中，我们讨论了抑制纳米药物进一步纳入患者护理的潜在障碍，克服这些障碍的可能策略，以及基于纳米技术的癌症干预措施的新方向。本文提出的见解是在最近由国家癌症研究所（NCI）主办的战略研讨会上举行的讨论的结果，该研讨会汇集了纳米医学领域的研究，临床和商业领导者。
Research activity in medical and cancer nanotechnology has grown dramatically over the past 15 years. The field has become a cradle of multidisciplinary investigations bringing together physicists, chemists, and engineers working with clinicians and biologists to address paramount problems in cancer care and treatment. Some have argued that the explosion in the number of research papers has not been followed by sufficient clinical activity in nanomedicine. However, three new nanodrugs have now been approved by the U.S. Food and Drug Administration (FDA) in the past three years, confirming the validity of nanotechnology approaches in cancer. Excitingly, translational pipelines contain several additional intriguing candidates. In this Nano Focus article, we discuss potential barriers inhibiting further incorporation of nanomedicines into patient care, possible strategies to overcome these barriers, and promising new directions in cancer interventions based on nanotechnology. Insights presented herein are outcomes of discussions held at a recent strategic workshop hosted by the National Cancer Institute (NCI), which brought together research, clinical, and commercial leaders of the nanomedicine field.